Get the Stockscreener App
42.33
0.57%
0.24
After Hours:
42.33
Qiagen Nv stock is traded at $42.33, with a volume of 947.97K.
It is up +0.57% in the last 24 hours and up +0.50% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$42.09
Open:
$42.22
24h Volume:
947.97K
Relative Volume:
0.84
Market Cap:
$9.41B
Revenue:
$1.94B
Net Income/Loss:
$72.70M
P/E Ratio:
29.19
EPS:
1.45
Net Cash Flow:
$405.21M
1W Performance:
+0.57%
1M Performance:
+0.50%
6M Performance:
-5.98%
1Y Performance:
+1.73%
1-Day Range:
$42.04
$42.48
1-Week Range:
$40.35
$42.48
52-Week Range:
$39.03
$47.44
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| QGEN | 42.33 | 9.41B | 1.94B | 72.70M | 405.21M | 1.45 |
| TMO | 516.10 | 196.16B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 235.05 | 167.17B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 132.06 | 37.94B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 197.60 | 35.86B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 418.55 | 34.27B | 3.84B | 866.24M | 792.60M | 9.80 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Massachusetts Financial Services Co. MA Sells 79,145 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Jennison Associates LLC Boosts Holdings in Qiagen (NYSE:QGEN) - MarketBeat
QIAGEN NV : Jefferies is Neutral - Marketscreener.com
Qiagen (NYSE:QGEN) Stake Lowered by Nuance Investments LLC - MarketBeat
QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up - MSN
Analysts Set Qiagen (NYSE:QGEN) Price Target at $50.88 - MarketBeat
Qiagen (NYSE:QGEN) Shares Bought by Natixis Advisors LLC - MarketBeat
180,729 Shares in Qiagen (NYSE:QGEN) Purchased by Impax Asset Management Group plc - MarketBeat
QGEN Collaborates With McGill University Centre: Stock to Gain? - Yahoo Finance
Victory Capital Management Inc. Has $117.33 Million Stock Position in Qiagen (NYSE:QGEN) - MarketBeat
What is William Blair's Estimate for Qiagen FY2024 Earnings? - MarketBeat
Crossmark Global Holdings Inc. Sells 12,133 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Pharmahungary Group participates in ambitious EU EVEREST Project - European Biotechnology News
QIAGEN collaborates with McGill University to advance microbiome research - GlobeNewswire
QIAGEN Partners with McGill to Target $1.8B Microbiome Market in Major Research Deal | QGEN Stock News - StockTitan
Don't Overlook Qiagen (QGEN) International Revenue Trends While Assessing the Stock - Yahoo Finance
QIAGEN NV : UBS reiterates its Neutral rating - Marketscreener.com
Earnings call: QIAGEN tops Q3 expectations, raises 2024 EPS outlook - Investing.com India
Earnings call: QIAGEN tops Q3 expectations, raises 2024 EPS outlook By Investing.com - Investing.com Australia
Qiagen Non-GAAP EPS of $0.46 beats by $0.02, revenue of $459M beats by $2.09M - MSN
Wellington Management Group LLP's Strategic Acquisition of Qiage - GuruFocus.com
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term - Yahoo Finance
Qiagen NV (QGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - GuruFocus.com
Qiagen Reports Strong Q3 2024 Growth - TipRanks
Is There An Opportunity With Qiagen N.V.'s (NYSE:QGEN) 31% Undervaluation? - Yahoo Finance
QIAGEN NV : Deutsche Bank reaffirms its Buy rating - Marketscreener.com
Qiagen Q3 24 Earnings Conference Call At 9:30 AM ET - Nasdaq
QIAGEN : Markets hailed the Q3 beat + the profitability upgrade - Marketscreener.com
QIAGEN NV : Receives a Buy rating from Berenberg - Marketscreener.com
Qiagen (NYSE:QGEN) Shares Sold by Van ECK Associates Corp - MarketBeat
Qiagen N : QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full year 2024 adjusted EPS outlook - Marketscreener.com
QIAGEN NV : UBS reaffirms its Neutral rating - Marketscreener.com
Qiagen N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Diagnostics firm Qiagen reports rise in third-quarter revenue - Reuters
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook - The Manila Times
QIAGEN Q3 Earnings Surge: Sales Hit $502M, Boosts 2024 EPS Outlook | QGEN Stock News - StockTitan
Qiagen NV (QGEN) Q3 2024: Everything You Need to Know Ahead of E - GuruFocus.com
FDA clears fourth Qiagen test in 2024 - BioWorld Online
Qiagen NV (QGEN) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com
QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel - Yahoo Finance
Qiagen (QGEN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics - GlobeNewswire
Qiagen Receives FDA Clearance Of Qiastat-Dx Meningitis/Encephalitis Panel To Support Emergency Diagnostics - XM
Forsta AP Fonden Sells 18,586 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Qiagen (QGEN) Set to Announce Earnings on Wednesday - MarketBeat
Raymond James & Associates Trims Position in Qiagen (NYSE:QGEN) - MarketBeat
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - GlobeNewswire Inc.
QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment - GlobeNewswire
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):